Neuroprotective "agents" in surgery. Secret "agent" man, or common "agent" machine?
The search for clinically-effective neuroprotective agents has received enormous support in recent years--an estimated $200 million by pharmaceutical companies on clinical trials for traumatic brain injury alone. At the same time, the pathophysiology of brain injury has proved increasingly complex, rendering the likelihood of a single agent "magic bullet" even more remote. On the other hand, great progress continues with technology that makes surgery less invasive and less risky. One example is the application of endovascular techniques to treat coronary artery stenosis, where both the invasiveness of sternotomy and the significant neurological complication rate (due to microemboli showering the cerebral vasculature) can be eliminated. In this paper we review aspects of intraoperative neuroprotection both present and future. Explanations for the slow progress on pharmacologic neuroprotection during surgery are presented. Examples of technical advances that have had great impact on neuroprotection during surgery are given both from coronary artery stenosis surgery and from surgery for Parkinson's disease. To date, the progress in neuroprotection resulting from such technical advances is an order of magnitude greater than that resulting from pharmacologic agents used during surgery. The progress over the last 20 years in guidance during surgery (CT and MRI image-guidance) and in surgical access (endoscopic and endovascular techniques) will soon be complemented by advances in our ability to evaluate biological tissue intraoperatively in real-time. As an example of such technology, the NASA Smart Probe project is considered. In the long run (i.e., in 10 years or more), pharmacologic "agents" aimed at the complex pathophysiology of nervous system injury in man will be the key to true intraoperative neuroprotection. In the near term, however, it is more likely that mundane "agents" based on computers, microsensors, and microeffectors will be the major impetus to improved intraoperative neuroprotection.
Andrews
R J
RJ
NASA Ames Research Center, Moffett Field, California 94035, USA. nserja@ttuhsc.edu
D001026:Coronary Artery Bypass / Q000009:adverse effects; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000601:surgery; D005544:Forecasting; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009493:Neurosurgery / Q000639:trends; D010300:Parkinson Disease / Q000188:drug therapy* / Q000601:surgery; D013238:Stereotaxic Techniques; D014481:United States; D018557:United States National Aeronautics and Space Administration; D020535:Video-Assisted Surgery / Q000295:instrumentation* / Q000379:methods
D018696:Neuroprotective Agents